

## Review Form 1.6

|                          |  |
|--------------------------|--|
| Journal Name:            | <a href="#">Journal of Pharmaceutical Research International</a>                               |
| Manuscript Number:       | Ms_JPRI_75814  |
| Title of the Manuscript: | A COHORT-STUDY TO DETERMINE THE PREVALENCE OF PULMONARY MANIFESTATIONS IN RHEUMATOID ARTHRITIS |
| Type of the Article      | Original Research Article  |

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

**Review Form 1.6**

**PART 1: Review Comments**

|                                     | <b>Reviewer's comment</b>  | <b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|--|--|
| <b>Compulsory</b> REVISION comments | <p>In the methods, you wrote patient collection from Pakistan- however the Introduction states that evaluating Egyptian RA patients was the main objective of this study- will need to be consistent- is it Egypt or Pakistan?</p> <p>Please clearly list the inclusion and exclusion criteria.</p> <p>The conclusion is only one sentence and does not mention the final outcome measure. You list, "RA affected subjects showed more occurrence than expected"- occurrence of what? Please be specific.</p> <p>For the conclusion- you should also add a little more volume- possibly explain why you think pulmonary manifestations were more prevalent in RA patients? Any theories? Sum up what you think led to this condition.</p> <p>May consider adding clinical recommendations in the conclusion as well- Should these patients be screened more frequently than the general population? Can you make any other recommendations to help care for these patients- both preventative and treatment based?</p> |  |
| <b>Minor</b> REVISION comments      | <p>There are subtle grammatical errors, too numerous to specifically list, throughout the paper which should be fixed by proof reading by a native English speaker.</p> <p>You list 46.25% of patients showing symptoms of respiration dyspnea and conclude that RA affected subjects "showed more occurrence than expected." What then would be expected in the normal population? Do you have a statistic that you can cite to list what this rate is in the general population?</p>   |  |
| <b>Optional/General</b> comments    | <p>The authors did a nice job highlighting the incidence of pulmonary manifestations in the RA population, and do an overall good review of the literature. There is still room for improvement though.</p>  |  |

**PART 2:**

|   | <b>Reviewer's comment</b>  | <b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|---|--|--|
| <b>Are there ethical issues in this manuscript?</b> | <i>(If yes, Kindly please write down the ethical issues here in details)</i> |  |

**Reviewer Details:**

|                                  |                      |
|----------------------------------|----------------------|
| Name:                            | <b>Shachar Kenan</b> |
| Department, University & Country | <b>USA</b>           |